Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
Abstract Therapeutic treatment of severe COVID-19 infection involves the administration of multiple pharmacologic agents to reduce the risk of serious complications; this may result in drug interactions and possible adverse reactions and induced cardiotoxicity. The risk–benefit ratio associated with...
Guardado en:
Autores principales: | Antonio Vitiello, Francesco Ferrara |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SpringerOpen
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/40a3ae9a21a0429ea800947f1e0a5a57 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Coronavirus Disease 2019 and Cardiac Arrhythmias
por: Antoni Martínez-Rubio, et al.
Publicado: (2020) -
A Review of Driving Restrictions in Patients at Risk of Syncope and Cardiac Arrhythmias Associated with Sudden Incapacity: Differing Global Approaches to Regulation and Risk
por: Andrei D Margulescu, et al.
Publicado: (2019) -
The Role of Cardiac MRI in the Management of Ventricular Arrhythmias in Ischaemic and Non-ischaemic Dilated Cardiomyopathy
por: Tom Nelson, et al.
Publicado: (2019) -
Impact of pregnancy and risk factors for ventricular arrhythmias in women with tetralogy of Fallot
por: Mette E Estensen, et al.
Publicado: (2021) -
Correction: Impact of pregnancy and risk factors for ventricular arrhythmias in women with tetralogy of Fallot
Publicado: (2021)